濮阳东方医院看阳痿怎么收费(濮阳东方妇科医院好) (今日更新中)

General Motors recently announced that it would be shutting down five car factories in the United States and Canada and cutting 14,000 jobs. GM said at the time that factory workers would be offered jobs at other facilities where production is being increased and on Friday it offered an update on how things are going.Of the jobs GM plans to cut, 2,800 are hourly employees in the United States. These are generally assembly line workers who punch in and out for work each day as opposed to employees who are paid a salary.The automaker announced Friday that 1,100 of those hourly workers have volunteered to transfer to jobs at other factories, such as GM's Flint, Michigan, truck plant where heavy duty pickups are built and the Toledo transmission plant in Toledo, Ohio. Another 1,200 workers in that group are eligible for retirement, the company said.The US plants GM is shutting down are in Michigan, Ohio, and Maryland. These plants mostly made sedans, which have fallen out of favor as customers have shifted toward crossover SUVs and trucks.GM also said last month that Canadian workers would be offered jobs at other plants in that country.In total, the company announced it would cut 6,000 hourly and 8,000 salaried positions. In October, the company offered voluntary buyouts to 18,000 workers.GM CEO Mary Barra has said she wants to save money and reposition the company for future investments in autonomous driving technology and electric cars. She wants to do this now, she has said, rather than waiting and cutting jobs during an economic crisis."Today, we have a plan for the majority of employees currently working at our impacted plants in Maryland, Michigan, Ohio and Oshawa, Canada that includes job opportunities at other GM facilities," Barra tweeted Friday. "We're committed to doing the right thing, for the future of GM and our people." 1901

GERMANY — Bayer plans to slash thousands of jobs as part of a corporate overhaul following its acquisition of Monsanto.The chemicals and pharmaceuticals group said it would cut 12,000 jobs out of its global workforce of 118,000 by the end of 2021. A significant number of reductions will be made in its home market of Germany.More than 4,000 jobs will go at the company's crop sciences division, a consequence of Bayer's acquisition of US rival Monsanto earlier this year.Bayer (BAYRY) spent over billion buying Monsanto. To gain regulatory approval for the deal, Bayer agreed to sell assets including its seed business and some herbicide brands.The German company said in a statement on Thursday that it was considering whether to sell more assets, including the sunscreen business Coppertone and footwear brand Dr. Scholl's.It will get out of the business of animal health, and sell its 60% stake in Currenta, a company that provides services to chemical companies.Shares in Bayer have dropped by more than a third so far this year, in part because of concerns over the company's exposure to lawsuits involving Roundup, a weedkiller made by Monsanto.In August, San Francisco jurors awarded 9 million in damages to a former school groundskeeper who said his terminal cancer had been caused by the product.The damages were later reduced by a judge, but hundreds of other patients have made similar claims. Monsanto has said the product is safe when used as directed. 1481

GRAND RAPIDS, Mich. — As we get closer to a potential COVID-19 vaccine approval in the U.S., doctors are hoping the public actually gets the vaccine once it’s available.Recent polling from Pew Research shows about 60% of Americans say they would ‘definitely’ or ‘probably’ get a COVID-19 vaccine.Local infectious disease doctors tell WXMI that that number will be just enough to put a serious dent in infections, but the more immunity, the better.Dr. Andrew Jameson, the Division Chief for Infectious Disease at Mercy Health said, “I am optimistic for the first time in a while.”Dr. Jameson added that he’s seeing a bit of light at the end of a very long tunnel with a COVID vaccine approval potentially just days away.“I can tell you right now from what I’ve seen, from an efficacy standpoint, from a safety standpoint, I am going to be definitely getting the vaccine personally and I have zero issues of giving my family the vaccine when it’s available,” Dr. Jameson said.With two COVID-19 vaccines on deck for approval with the FDA, one from Pfizer and one from Moderna, Dr. Jameson is hoping that people feel confident in getting it once they’re able.“If we get about 60% of people immunized and then we also have the natural immunity out there giving us a little bit of extra help, I think that is going to be a huge impact,” Dr. Jameson said.Dr. Jameson said he also understands that people may be wary of such a new vaccine.“Unfortunately, we’ve had a fair amount of skepticism in the community about vaccines before all of this, and now in the setting of this being moved forward pretty quickly, I think there’s probably a little bit of a natural skepticism,” he said.He said the biggest reason he’s heard for not wanting the vaccine is that things are just moving too fast.“Before this, the fastest that we ever had a vaccine get from the beginning to the end to where people were getting it, was four years, and this one is going to be about 10 months,” Dr. Jameson said.Dr. Jameson called the trial and manufacturing process of both companies vaccines, ‘the most transparent’ he’s ever seen and trusts the FDA to leave no stone unturned before approval.“They get all the notes from the doctors, they get all the patient encounter visits from the sites that are doing the vaccine, so they actually get all of the raw data and re-interpret it and re-analyze it themselves for efficacy, so they don’t just believe what the drug manufacturers tell them,” he explained.He wants people to also understand potential vaccine side effects, to make sure they come back for their second dose. Both Moderna and Pfizer vaccines require two doses given several weeks apart to reach full effectiveness.“If I know that my arm is going to hurt, and I might have a headache, and I might feel run-down for a day or two, if I know that, it’s very different than if that’s a surprise to me,” he said.The FDA is scheduled to meet on Thursday to review the Pfizer vaccine and then again on Dec. 17 to look over Moderna’s vaccine.This story was first reported by Annie Szatkowski at WXMI in Grand Rapids, Michigan. 3109

Having an adequate supply of personal protective equipment could have saved the state of California hundreds of millions of dollars and stopped roughly 18,000 essential workers from getting the coronavirus, according to a new study from the University of California Berkeley.Researchers at the school looked at the cost of PPE and the early costs and infection rates of coronavirus in California. They conclude with a recommendation that the state stockpile PPE for a future pandemic.The team’s first data point is based on supply and demand; purchasing PPE when it is not high in demand, then saving it for when it's needed. According to the study, the cost of purchasing the same amount of PPE when there was not a global demand would be 17 percent of what the projected cost is now during the pandemic.“Maintaining the stockpile would be cheaper than real-time purchases even if it was not needed for another 35 years, and even if we were fortunate enough to not need the stockpile for longer than that, it would be a highly financially prudent form of insurance,” the researchers stated.Between mid-March and mid-July, roughly 250,000 healthcare workers in California filed for unemployment benefits because there was not sufficient PPE for them to go to work.For each week those healthcare workers could not report to work, it cost the state million in unemployment benefits. The researchers conclude millions could be saved by having the personal protective equipment available.Looking at rates of infection and studies from Europe showing transmission rates at hospitals, Berkeley researches believe almost 18,000 coronavirus cases among essential workers could have been prevented with an adequate supply of PPE.“If those worker cases had been avoided, an estimated 3,030 secondary cases among household members could have also been avoided, thus totaling at least 20,860 cases that could have been averted,” the study states.A separate survey conducted in June and July asked California’s skilled nursing facility staff about equipment; more than 20 percent reported still having inadequate supplies of PPE, and 80 percent said they were very or extremely concerned about workplace infection.The Berkeley study also appears to give support to California Senate Bill 275 as amended in July 2020, that “would require the state to create a PPE stockpile sufficient to protect healthcare and other essential workers for at least 90-days of a future pandemic or health emergency.” 2496

HORTONVILLE, Wis — Benshot, a northeast Wisconsin company that produces glassware embedded with bullets, gifted handguns to staff as an early Christmas present. The company staffs 16 full-time employees and gifted the handguns as an effort to promote personal safety and team building, according to the The Post Crescent.Owner Ben Wolfram told the paper that this is the first time in their three years of business that they've gifted guns to workers. He said he does not fear a possibility of workplace violence because the staff is so small and close-knit.  627

来源：资阳报